We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough.
The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2).’ was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
- What are the greatest challenges in the management of people with chronic cough? (0:17)
- What is the rationale for the use of gefapixant in the treatment of chronic cough? (1:52)
- Could you tell us a little about the COUGH-1 and COUGH-2 studies? (3:09)
- What were the findings of the pooled analysis of the COUGH-1 and COUGH-2 study data? (5:03)
- What will be the likely place of gefapixant in the treatment paradigm for chronic cough? (6:02)
Disclosures: Jacky Smith discloses consultancy work and delivery of clinical trials for Merck, Bayer, Bellus Health and Shionogi. Collaboration with Vitalograph Ltd and License agreement between Vitalograph and hospital, who receive royalties.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATSÂ 2021 (Virtual).
